Cortoss to target vertebral compression fractures:
This article was originally published in Clinica
Orthovita says that it plans to submit to European regulatory authorities by the end of 2002 data from a study that is assessing its Cortoss biomaterial as a means of repairing vertebral compression fractures. Cortoss, a synthetic cortical bone void filler, has been on sale in Europe since January 2002 for the fixation of bone screws used in patients with weak bone caused by osteoporosis. The new study is evaluating the ability of the product to provide pain relief by providing new stability to the fractured vertebra, says the Malvern, Pennsylvania firm.
You may also be interested in...
Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma
The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program.
Johnson & Johnson believes personalization via digital holds the key to smoking cessation success as it launches in the UK its app-supported Nicorette QuickMist SmartTrack product.